On the evening of June 3, Sino-platinum metals announced that its wholly-owned subsidiary, Guizhou Research Chemical Materials (Yunnan) Co., Ltd., plans to invest CNY 100 million to establish a wholly-owned subsidiary, Guizhou Research Chemical Pharmaceutical Technology (Yunnan) Co., Ltd. (referred to as "Guizhou Research Chemical Pharmaceutical Company"). With the construction of the "Platinum Anti-Cancer Drug Active Pharmaceutical Ingredient Industrialization Project" as the basis, it will extend the downstream processing and complement the company's precious metal APIs to strive to become a mainstream supplier in the domestic market. At the same time, it will continue to promote the research and development and incubation of new precious metal anti-cancer drugs, transform and construct a precious metal raw material medicine base covering production and research and development, and continuously strengthen the company's life and health industry application field.
贵研铂业6月3日晚间公告公司下属全资子公司贵研化学材料（云南）有限公司拟投资1亿元设立全资子公司贵研化学制药科技（云南）有限公司（简称“贵研化学制药公司”）。以“铂抗癌药物原料药产业化项目”的建设为依托将贵金属抗癌药物原料药前驱体产品向下游加工延伸补足公司贵金属原料药的产业短板力争打造成为国内主流供应商。同时持续推动新型贵金属抗癌药物研发及孵化转型构建涵盖生产和研发的贵金属原料药基地持续壮大公司生命健康产业应用领域。
On the evening of June 3, Sino-platinum metals announced that its wholly-owned subsidiary, Guizhou Research Chemical Materials (Yunnan) Co., Ltd., plans to invest CNY 100 million to establish a wholly-owned subsidiary, Guizhou Research Chemical Pharmaceut
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.